KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Current Investments (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Cash & Current Investments for 9 consecutive years, with $185.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 14.39% year-over-year to $185.2 million, compared with a TTM value of $185.2 million through Dec 2025, down 14.39%, and an annual FY2025 reading of $185.2 million, down 14.39% over the prior year.
  • Cash & Current Investments was $185.2 million for Q4 2025 at Biocryst Pharmaceuticals, down from $212.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $389.0 million in Q4 2023 and bottomed at $172.5 million in Q2 2025.
  • Average Cash & Current Investments over 3 years is $250.8 million, with a median of $246.4 million recorded in 2023.
  • Peak annual rise in Cash & Current Investments hit 32.93% in 2024, while the deepest fall reached 44.38% in 2024.
  • Year by year, Cash & Current Investments stood at $389.0 million in 2023, then plummeted by 44.38% to $216.3 million in 2024, then dropped by 14.39% to $185.2 million in 2025.
  • Business Quant data shows Cash & Current Investments for BCRX at $185.2 million in Q4 2025, $212.9 million in Q3 2025, and $172.5 million in Q2 2025.